Teriparatide Treatment in Patients with Pregnancy- and Lactation-Associated Osteoporosis

AbstractPregnancy- and lactation-associated osteoporosis (PLO) is a rare disease, presenting in most cases with severe back pain due to low energy vertebral fractures (VFs). Our purpose was to assess the effect of teriparatide (TPTD)vs. conventional management on areal bone mineral density (aBMD) and trabecular bone score (TBS) in patients with PLO. A multicenter retrospective cohort study concerning premenopausal women with PLO. Nineteen women were treated with TPTD (20  μg/day) (group A) plus calcium and vitamin D and eight women with calcium and vitamin D only (group B) for up to 24 months. The primary end-point was between group differences in lumbar spine (LS) and total hip (TH) aBMD, and TBS at 12 and 24 months. Patients in group A had sustained a median o f 4.0 VFs (3–9)vs. 2.5 VFs (1 –10) in group B (p = 0.02). At 12 months, patients on TPTDvs. controls achieved a mean aBMD increase of 20.9   ±  11.9%vs. 6.2   ±  4.8% at the LS (p <  0.001), 10.0  ±  11.6%vs. 5.8   ±  2.8% at the TH (p = 0.43), and 6.7  ±  6.9%vs. 0.9   ±  3.7% in TBS (p = 0.09), respectively. At 24 months, seven patients on TPTD and six controls achieved a mean LS aBMD increase of 32.9  ±  13.4%vs. 12.2   ±  4.2% (p = 0.001). P1NP levels during the first month of TPTD treatment were positively correlated with the 1-year LS aBMD change (r = 0.68,p = 0.03). No new clinical fractures occurred while on-treatm...
Source: Calcified Tissue International - Category: Orthopaedics Source Type: research